A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To study the effect of mild and moderate hepatic impairment on the pharmacokinetics (PK) of
eliglustat.
Secondary Objective:
To assess the tolerability of eliglustat tartrate given as a single dose in subjects with
mild and moderate hepatic impairment in comparison with matched subjects with normal hepatic
function.